You are here

Article Text

Article menu
Download PDFPDF
Editorial
Atrial fibrillation phenotypes: the route to personalised care?
  1. Arunashis Sau1,2,
  2. Libor Pastika1,3,
  3. Fu Siong Ng1,2,3
  1. 1 National Heart and Lung Institute, Imperial College London, London, UK
  2. 2 Department of Cardiology, Imperial College Healthcare NHS Trust, London, UK
  3. 3 Department of Cardiology, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK
  1. Correspondence to Dr Fu Siong Ng, National Heart and Lung Institute, Imperial College London, SW7 2BX, London, UK; f.ng{at}imperial.ac.uk

https://doi.org/10.1136/heartjnl-2023-322812

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Atrial fibrillation (AF) is the most common arrhythmia in adults and is responsible for significant morbidity and mortality. Recent data support the move towards personalisation of care in AF, which is of particular importance given the multiple, complex, management decisions that need to be made. Paradigms in AF care have also changed significantly recently due to the results of EAST-AFNET 41 that demonstrated the benefits of rhythm control for the reduction in adverse cardiovascular outcomes.

    Catheter ablation is used increasingly in AF for the improvement of symptoms and potentially the reduction of adverse events in certain populations. However, there is a currently a ceiling to the success rates of catheter ablation in AF. Several additional lesion sets beyond pulmonary vein isolation have been advocated; however, none have been reliably shown to be beneficial in unselected patients.2 Tailoring of treatments based on AF phenotype may therefore be important in improving success rates of existing treatments.3 The recent ERASE-AF trial highlights the potential for personalised approaches to improve care for …

    View Full Text

    Footnotes

    • Twitter @arunsau_, @LiborPastika, @DrFuSiongNg

    • Contributors AS, LP and FSN drafted and revised the manuscript.

    • Funding This study was funded by British Heart Foundation (FS/CRTF/21/24183, RG/F/22/110078).

    • Competing interests FSN is an inventor of a patent application on Granger Causality mapping.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles